Safety and Efficacy of Home-Based Exercise Rehabilitation Using Remote Monitoring in New Left Ventricular Assist Device Recipients
Data on home-based exercise rehabilitation (HER), using a wearable activity monitor and smartphone app, are limited in LVAD recipients. The purpose of the MOVE-LVAD study is to evaluate the feasibility, safety, and effects of HER on activity levels and healthcare utilization in newly implanted Heart...
Saved in:
| Published in: | The Journal of heart and lung transplantation Vol. 41; no. 4; pp. S65 - S66 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Elsevier Inc
01-04-2022
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Data on home-based exercise rehabilitation (HER), using a wearable activity monitor and smartphone app, are limited in LVAD recipients. The purpose of the MOVE-LVAD study is to evaluate the feasibility, safety, and effects of HER on activity levels and healthcare utilization in newly implanted HeartMate 3 (HM3) LVAD patients.
MOVE-LVAD is a randomized study conducted at a single center. We aim to enroll 30 subjects, and here we provide data on the first 14 patients. Subjects in the HER and usual care (UC) groups wear an activity watch to monitor steps. In the HER group, patients also use a smartphone app to rate perceived exertion on the Borg scale and complete video calls with an exercise physiologist. Borg rating and daily steps are used to titrate exercise prescriptions. Endpoints include mean steps and rehospitalization. Mean daily steps are calculated for individual patients during weeks 1, 4, 8, and 12, and averages at each timepoint for the HER and UC groups are calculated separately.
We provide data for the first 14 subjects during 3-month follow-up. 6 patients (mean age 60 years, 83% male) were randomized to HER and 8 (mean age 56 years, 88% male) to UC. During week 1, mean daily steps were 1595 ± 1579 in the HER group and 1436 ± 1031 in the UC group (Figure). During week 12, mean daily steps were 3705 ± 2628 in the HER group and 1669 ± 991 in the UC group. From week 1 to week 12, the average increase in daily steps was 1711 ± 1106 in the HER group and 587 ± 923 in the UC group. HER was not associated with any adverse events. There were 0 rehospitalizations in the HER group and 7 rehospitalizations in the UC group in 4 separate patients.
Initial data from the MOVE-LVAD study suggest that HER with remote monitoring is feasible, safe, and may be associated with a greater increase in daily activity levels and lower rehospitalization rate compared to UC in newly implanted HM3 LVAD patients. Larger studies are needed to determine the effects of HER on long-term outcomes. |
|---|---|
| ISSN: | 1053-2498 1557-3117 |
| DOI: | 10.1016/j.healun.2022.01.151 |